» Articles » PMID: 15164808

Out-of-pocket Health-care Expenditures Among Older Americans with Cancer

Overview
Journal Value Health
Publisher Elsevier
Date 2004 May 29
PMID 15164808
Citations 62
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: There is currently limited information regarding the out-of-pocket expenditures (OOPE) for medical care made by elderly individuals with cancer. We sought to quantify OOPE for community-dwelling individuals age 70 or older with: 1) no cancer (No CA), 2) a history of cancer, not undergoing current treatment (CA/No Tx), and 3) a history of cancer, undergoing current treatment (CA/Tx).

Methods: We used data from the 1995 Asset and Health Dynamics Study, a nationally representative survey of community-dwelling elderly individuals. Respondents identified their cancer status and reported OOPE for the prior 2 years for: 1) hospital and nursing home stays, 2) outpatient services, 3) home care, and 4) prescription medications. Using a multivariable two-part regression model to control for differences in sociodemographics, living situation, functional limitations, comorbid chronic conditions, and insurance coverage, the additional cancer-related OOPE were estimated.

Results: Of the 6370 respondents, 5382 (84%) reported No CA, 812 (13%) reported CA/No Tx, and 176 (3%) reported CA/Tx. The adjusted mean annual OOPE for the No CA, CA/No Tx, and CA/Tx groups were 1210 dollars, 1450 dollars, and 1880 dollars, respectively (P < .01). Prescription medications (1120 dollars per year) and home care services (250 dollars) accounted for most of the additional OOPE associated with cancer treatment. Low-income individuals undergoing cancer treatment spent about 27% of their yearly income on OOPE compared to only 5% of yearly income for high-income individuals with no cancer history (P < .01).

Conclusions: Cancer treatment in older individuals results in significant OOPE, mainly for prescription medications and home care services. Economic evaluations and public policies aimed at cancer prevention and treatment should take note of the significant OOPE made by older Americans with cancer.

Citing Articles

Development and validation of FinTox: A new screening tool to assess cancer-related financial toxicity.

Badr H, Han J, Mims M Cancer Med. 2024; 13(15):e7306.

PMID: 39113222 PMC: 11306290. DOI: 10.1002/cam4.7306.


Catastrophic health expenditures, insurance churn, and non-employment among women with breast cancer.

Berlin N, Albright B, Moss H, Offodile 2nd A JNCI Cancer Spectr. 2024; 8(2).

PMID: 38331405 PMC: 11003299. DOI: 10.1093/jncics/pkae006.


Financial Toxicity in Swiss Cancer Patients Treated with Proton Therapy: An Observational Cross-Sectional Study on Self-Reported Outcome.

Bachtiary B, Grawehr L, Ruggieri F, Held U, Weber D Cancers (Basel). 2023; 15(23).

PMID: 38067202 PMC: 10705792. DOI: 10.3390/cancers15235498.


Evaluating Work Impairment as a Source of Financial Toxicity in Cancer Healthcare and Negative Impacts on Health Status.

Mudaranthakam D, Nollen N, Wick J, Hughes D, Welch D, Calhoun E Cancer Res Commun. 2023; 3(7):1166-1172.

PMID: 37415746 PMC: 10321355. DOI: 10.1158/2767-9764.CRC-23-0038.


Career disruption and limitation of financial earnings due to cancer.

Mudaranthakam D, Hughes D, Johnson P, Mason T, Nollen N, Wick J JNCI Cancer Spectr. 2023; 7(4).

PMID: 37326961 PMC: 10359624. DOI: 10.1093/jncics/pkad044.